Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004581 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
A Phase 3 study of HIV Infections, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00004581: Completed Phase 3 study of HIV Infections, sponsored by Abbott.
NCT00004581 is a Phase 3 study of HIV Infections that has completed, run by Abbott. The registered enrollment target is 300 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004581, a Phase 3 study of HIV Infections, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors (NRTIs), and at least 1 protease inhibitor (PI). One combination will include a new protease inhibitor, ABT-378, combined in a capsule with ritonavir (RTV).
Conditions Studied
Interventions
- DRUG Nevirapine
- DRUG Lopinavir/Ritonavir
Study Locations (20)
California
- Pacific Oaks Med Group - Beverly Hills
- Orange County Ctr for Special Immunology - Fountain Valley
- AIDS Healthcare Foundation - Los Angeles
- Tower ID Med Associates - Los Angeles
- UCLA CARE Ctr - Los Angeles
- San Francisco Veterans Administration Med Ctr - San Francisco
- Harbor - UCLA Med Ctr - Torrance
Florida
- Univ of Miami School of Medicine - Miami
- Infectious Disease Research Institute - Tampa
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
- Emory Univ - Atlanta
Illinois
- Cook County Hosp - Chicago
- AIDS Research Alliance - Chicago - Chicago
Alabama
- Univ of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Body Positive - Phoenix
Connecticut
- Yale Univ / AIDS Clinical Trials Unit - New Haven
Indiana
- Division of Inf Diseases/ Indiana Univ Hosp - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Phase | Phase 3 |
What the finished NCT00004581 record still lists
NCT00004581 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Nevirapine is the first listed.
NCT00004581 names 20 study sites across 11 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00004581 about?
NCT00004581 is a clinical study titled "A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment". The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors (NRTIs), and at least 1 protease inhibitor (PI). One combination will include ...
What is the current status of trial NCT00004581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants.
What conditions does trial NCT00004581 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00004581?
The interventions under investigation include: Nevirapine (DRUG), Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00004581?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004581 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004581's enrollment target sits among peer trials
300 115th of 542 higher than 417 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics